Due to health issues, this site is no longer maintained and will be shut down shortly. |
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company focuses on developing its novel tri-specific Nanobody Sonelokimab (SLK), an IL-17A and IL-17F inhibitor, in multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
$22.51 +1.49 (7.09%)
As of 03/27/2023 13:59:04 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.